octreotide acetate · Chiesi · NDA 208232
Mycapssa
Earliest generic entry, as listed
28 Dec 2040
Blocked by patent: US 11141457, US 11890316. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 16 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11141457 | use U-3232 · sets the listed date | 28 Dec 2040 |
| US 11890316 | use U-3232 · sets the listed date | 28 Dec 2040 |
| US 10238709 | use U-2857 | 3 Feb 2036 |
| US 10695397 | use U-2857 | 3 Feb 2036 |
| US 11052126 | use U-2857 | 3 Feb 2036 |
| US 11338011 | use U-2857 | 3 Feb 2036 |
| US 11510963 | use U-2857 | 3 Feb 2036 |
| US 11857595 | use U-3784 | 3 Feb 2036 |
| US 12246054 | use U-2857 | 3 Feb 2036 |
| US 12251418 | use U-2857 | 3 Feb 2036 |
| US 11969471 | drug product | 17 Sep 2029 |
| US 11986529 | use U-2857 | 17 Sep 2029 |
| US 8329198 | drug product | 17 Sep 2029 |
| US 8535695 | use U-2857 | 17 Sep 2029 |
| US 9265812 | drug product | 17 Sep 2029 |
| US 9566246 | drug product | 17 Sep 2029 |
Exclusivities · 1 unexpired
| ODE-474 | orphan drug (7 years) | 26 Jun 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208232 · 001 · RLD | capsule, delayed release, oral | EQ 20MG BASE | 28 Dec 2040 |